• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Crit Care Explor . Interleukin-7 Reverses Lymphopenia and Improves T-Cell Function in Coronavirus Disease 2019 Patient With Inborn Error of Toll-Lik

tetano

Editor, Senior Moderator
Crit Care Explor


. 2021 Jul 14;3(7):e0500.
doi: 10.1097/CCE.0000000000000500. eCollection 2021 Jul.
Interleukin-7 Reverses Lymphopenia and Improves T-Cell Function in Coronavirus Disease 2019 Patient With Inborn Error of Toll-Like Receptor 3: A Case Report


Monty B Mazer[SUP] 1 [/SUP], Isaiah R Turnbull[SUP] 2 [/SUP], Sydney Miles[SUP] 1 [/SUP], Teresa M Blood[SUP] 1 [/SUP], Brooke Sadler[SUP] 3 4 [/SUP], Annie Hess[SUP] 2 [/SUP], Mitchell D Botney[SUP] 5 [/SUP], Robert S Martin[SUP] 5 [/SUP], James P Bosanquet[SUP] 5 [/SUP], David A Striker[SUP] 5 [/SUP], Nitin S Anand[SUP] 5 [/SUP], Michel Morre[SUP] 6 [/SUP], Charles C Caldwell[SUP] 7 [/SUP], Scott C Brakenridge[SUP] 8 [/SUP], Lyle L Moldawer[SUP] 8 [/SUP], Jorge A Di Paola[SUP] 3 [/SUP], Richard S Hotchkiss[SUP] 1 2 9 [/SUP], Kenneth E Remy[SUP] 1 9 10 [/SUP]



Affiliations

Abstract

Background: Immunotherapy treatment for coronavirus disease 2019 combined with antiviral therapy and supportive care remains under intense investigation. However, the capacity to distinguish patients who would benefit from immunosuppressive or immune stimulatory therapies remains insufficient. Here, we present a patient with severe coronavirus disease 2019 with a defective immune response, treated successfully with interleukin-7 on compassionate basis with resultant improved adaptive immune function.
Case summary: A previously healthy 43-year-old male developed severe acute respiratory distress syndrome due to the severe acute respiratory syndrome coronavirus 2 virus with acute hypoxemic respiratory failure and persistent, profound lymphopenia. Functional analysis demonstrated depressed lymphocyte function and few antigen-specific T cells. Interleukin-7 administration resulted in reversal of lymphopenia and improved T-cell function. Respiratory function and clinical status rapidly improved, and he was discharged home. Whole exome sequencing identified a deleterious autosomal dominant mutation in TICAM1, associated with a dysfunctional type I interferon antiviral response with increased severity of coronavirus disease 2019 disease.
Conclusions: Immunoadjuvant therapies to boost host immunity may be efficacious in life-threatening severe coronavirus disease 2019 infections, particularly by applying a precision medicine approach in selecting patients expressing an immunosuppressive phenotype.

Keywords: case report; coronavirus disease 2019; immunotherapy; interferons; interleukin-7; toll-like receptor 3.
 
Back
Top Bottom